SCHEMBL5519442

SCHEMBL5519442

NC(=O)Nc1c(Cl)c(Cl)cc(Cl)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
HPGD P15428 3/20 0.39
HSD17B10 Q99714 3/20 0.39
TSHR P16473 2/20 0.39
CASP1 P29466 1/20 0.39
CYP3A4 P08684 2/20 0.38
CYP1A2 P05177 1/20 0.36
HSPA5 P11021 1/20 0.36
MAPK1 P28482 1/20 0.36
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
PEPD P12955 1/20 0.35
HSD11B1 P28845 1/20 0.35
ALDH1A1 P00352 2/20 0.34
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11426891 0.87 NPC1 (0.41) NPC1HPGDHSD17B10TSHRCASP1
SCHEMBL5155916 0.80 NPC1 (0.47) NPC1CYP1A2PEPDALDH1A1GAA
SCHEMBL8742371 0.77 HPGD (0.39) NPC1HPGDHSD17B10TSHRCASP1
SCHEMBL5520771 0.77 KMT2A (0.39) HPGDHSD17B10TSHRCASP1CYP3A4
SCHEMBL374388 0.77 NPC1 (0.48) NPC1HPGDHSD17B10TSHRCYP3A4
SCHEMBL9164339 0.77 GAA (0.53) HPGDHSD17B10TSHRCASP1CYP3A4
SCHEMBL10811275 0.77 CA1 (0.32) HPGDHSD17B10TSHRCASP1CYP3A4
SCHEMBL4199091 0.74 CYP1A2 (0.42) NPC1HPGDHSD17B10TSHRCYP3A4
SCHEMBL18131073 0.74 ALDH1A1 (0.41) CYP1A2ALDH1A1GAAKDM4E
SCHEMBL5529517 0.73 CYP1A2 (0.44) NPC1CYP1A2ALDH1A1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 NPC1 412/4885HPGD 3176/4885HSD17B10 1087/4885
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 NPC1 778/4885HPGD 2310/4885HSD17B10 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.